CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

Summary

First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.

Timeline

Start

2024-02-15

Primary completion

2031-06-15

Completion

2031-12-31

Publications

• Silkenstedt E, Dreyling M. First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70073. doi: 10.1002/hon.70073.

Drugs

Indications